Paris and Boston, July 6, 2022 – 6:00 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces today Today the publication of a new meta-analysis titled “High definition probe based confocal laser endomicroscopy review and meta-analysis for neoplasia detection in Barrett’s esophagus” in Techniques and Innovations in Gastrointestinal Endoscopy (TIGE), a peer-reviewed journal.
Study demonstrates that adding endomicroscopy with Cellvizio as an adjunct to guide biopsies provides significantly higher diagnostic yield for dysplasia and cancer and reduces sampling error compared to random four-quadrant biopsies alone , constituting the standard method of diagnosis.
“The results of these studies demonstrate that there are better tools readily available to physicians that can improve the detection rate of screening and surveillance programs, and ultimately reverse the alarming rise in the prevalence of breast cancer. esophagus,” said Nicolas Bouvier, Acting Chief Executive Officer of Mauna Kea Technologies. “Better detection rates and lower healthcare utilization make Cellvizio a valuable addition to the standard diagnostic method in hospitals and clinics outpatient surgery centers. »